We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04346225
Recruitment Status : Recruiting
First Posted : April 15, 2020
Last Update Posted : July 29, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rahul Aggarwal, University of California, San Francisco

Brief Summary:
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients. In the proposed study, the investigators aim is to extend the initial clinical results and further develop HP C-13 MRI as an imaging modality in advanced prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Advanced Prostate Carcinoma Drug: Hyperpolarized C13 Procedure: Magnetic Resonance Imaging (MRI) Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the kPL (metabolic flux from hyperpolarized [HP] [1-13C]pyruvate to [1-13C]lactate) and kPG (metabolic flux from HP [2-13C]pyruvate to [5-13C]glutamate) within target lesion. (Cohort A) II. To determine the mean percent change from baseline in intra-tumoral kPL and kPG within target lesion. (Cohort B)

SECONDARY OBJECTIVE:

I. To descriptively report on the intra-tumor heterogeneity in kPL and kPG measurement within target lesion. (Cohorts A and B)

EXPLORATORY (CORRELATIVE) OBJECTIVES:

I. To determine if the change from baseline in kPL and kPG is associated with subsequent clinical outcomes on treatment including prostate specific antigen (PSA) response rate and radiographic progression-survival by Prostate Cancer Working Group 3 (PCWG3) criteria. (Cohort B) II. In target lesions that are measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, to determine whether baseline and/or change from baseline in intratumoral kPL and kPG is associated with subsequent objective response by RECIST criteria. (Cohort B) III. To determine the mean percent change from baseline in peak intra- tumoral HP lactate (lac)/pyruvate (pyr) and glutamate (glu)/pyr ratios on repeat metabolic magnetic resonance imaging (MRI) obtained at the time of radiographic disease progression by PCWG3 criteria. (Cohort B) IV. To investigate for association between HP kPL and kPG as well as area under the curve (AUC) lac/pyr and glu/pyr ratios with tissue- based markers of elevated lactate and glutamate metabolism including MYC and LDHA and PDH protein expression. (In participants who undergo optional tumor biopsy [Cohort A or B]) V. To investigate for an association between HP kPL and kPG as well as area under the curve (AUC) lac/pyr and glu/pyr ratios with histologic evidence of small cell/neuroendocrine differentiation. (In participants who undergo optional tumor biopsy [Cohort A or B])

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT A (SINGLE TIME-POINT): Patients receive C-1 labeled hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than 1 minute then undergo magnetic resonance spectroscopic imaging (MRSI) over less than 5 minutes. Patients may also receive an optional C-2 labeled hyperpolarized carbon C 13 pyruvate IV and undergo MRSI within 15-60 minutes following completion of the first scan.

COHORT B (MULTIPLE TIME-POINT): Patients receive C-1 labeled hyperpolarized carbon C 13 pyruvate IV over less than 1 minute then undergo MRSI over less than 5 minutes. Patients may also receive an optional C-2 labeled hyperpolarized carbon C 13 pyruvate IV and undergo MRSI within 15-60 minutes following completion of the first scan at baseline and 12 weeks.

After completion of study treatment, patients are followed up periodically.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer
Actual Study Start Date : July 16, 2020
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : November 30, 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A: Hyperpolarized C13 MRI at a single time point
Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
Drug: Hyperpolarized C13
Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
Other Name: HP [1-13C]pyruvate

Procedure: Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
Other Name: Magnetic Resonance

Experimental: Cohort B: Hyperpolarized C13 MRI at multiple time points
Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 12 weeks (+/- 8 weeks). Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as well.
Drug: Hyperpolarized C13
Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
Other Name: HP [1-13C]pyruvate

Procedure: Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
Other Name: Magnetic Resonance




Primary Outcome Measures :
  1. Pyruvate to lactate (kPL) metabolic flux within target lesion (Cohort A) [ Time Frame: 1 day ]
    The metabolic flux of kPL within the target lesion will be determined for each participant enrolled in Cohort A. Descriptive statistics will be used to summarize the kPL measurements with the mean, standard deviation, and 95% confidence interval

  2. Pyruvate to glutamate (kPG) metabolic flux within target lesion (Cohort A). [ Time Frame: 1 day ]
    The metabolic flux of kPG within the target lesion will be determined for each participant enrolled in Cohort A. Descriptive statistics will be used to summarize the kPG measurements with the mean, standard deviation, and 95% confidence interval

  3. Mean percent change from baseline in intra-tumoral kPL within target lesion after treatment. (Cohort B) [ Time Frame: Up to 8 weeks ]
    The mean percent change from baseline in intra-tumoral kPL to repeat metabolic MRI obtained at the time of radiographic disease progression by PCWG3 criteria will be descriptively reported for the entire study cohort and for the subgroups of participants with treatment- refractory and treatment-responsive prostate cancer. A paired t-test or signed rank Wilcoxon test will be used to compare follow up versus baseline kPL in target lesion in participants enrolled in Cohort B.

  4. Mean percent change from baseline in intra-tumoral kPG within target lesion after treatment. [ Time Frame: Up to 8 weeks ]
    The mean percent change from baseline in intra-tumoral kPG to repeat metabolic MRI obtained at the time of radiographic disease progression by PCWG3 criteria will be descriptively reported for the entire study cohort and for the subgroups of participants with treatment- refractory and treatment-responsive prostate cancer. A paired t-test or signed rank Wilcoxon test will be used to compare follow up versus baseline kPG in target lesion in participants enrolled in Cohort B.


Secondary Outcome Measures :
  1. Intra-tumoral range of kPL measurement within target lesion [ Time Frame: Up to 1 year ]
    The mean, standard deviation, and range for intra-tumoral kPG within metastatic lesions will be descriptively reported, to asses for intra-tumoral heterogeneity.

  2. Intra-tumoral range of kPG measurement within target lesion [ Time Frame: Up to 1 year ]
    The mean, standard deviation, and range for intra-tumoral kPG within metastatic lesions will be descriptively reported, to asses for intra-tumoral heterogeneity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically-confirmed locally advanced or metastatic prostate cancer. Patients with unequivocal clinical evidence supporting diagnosis of prostate cancer who have not had prior biopsy may be considered eligible per judgment of Principal Investigator.
  2. Presence of at least one target lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:

    1. Soft tissue/visceral organ target lesions must measure at 1 cm in long axis diameter on CT or MRI.
    2. Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify).
    3. For patients with target lesion in prostate/prostatic bed:

    i. No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).

    ii. No prior local treatment to the selected lesion, or evidence of radiographic progression following prior local therapy to selected lesion.

  3. Able and willing to comply with study procedures and provide signed and dated informed consent.
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  5. For patients undergoing optional tumor biopsy:

    1. No history of bleeding diathesis.
    2. Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.

Exclusion Criteria:

  1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
  2. Patients unwilling or unable to undergo MR imaging, including patients with contra- indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
  3. Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MRI.
  4. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04346225


Contacts
Layout table for location contacts
Contact: Maya Aslam 877-827-3222 Maya.Aslam@ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Maya Aslam    877-827-3222    Maya.Aslam@ucsf.edu   
Contact       cancertrials@ucsf.edu   
Sub-Investigator: John Kurhanewicz, PhD         
Principal Investigator: Rahul Aggarwal, MD         
Sponsors and Collaborators
Rahul Aggarwal
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Rahul Aggarwahl, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: Rahul Aggarwal, Associate Clinical Professor, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04346225    
Other Study ID Numbers: 20922
R01CA215694 ( U.S. NIH Grant/Contract )
First Posted: April 15, 2020    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rahul Aggarwal, University of California, San Francisco:
Prostate Cancer
Hyperpolarized Pyruvate (13C)
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases